Street canvu MBX phase II HP data more than one way
· randy osborne
AI Briefing
- • MBX Biosciences Inc. releases full phase II results for canvuparatide, a PTH peptide prodrug.
- • Results compare canvuparatide to Ascendis Pharma's Yorvipath, a PTH analog FDA-cleared for HP.
- • Canvu is stacked against Yorvipath in odds of success for HP treatment.
Context
MBX Biosciences Inc. has obtained full phase II results for canvuparatide, a parathyroid hormone peptide prodrug. The results will be used to compare canvuparatide to Yorvipath, a PTH analog from Ascendis Pharma A/S.
The comparison matters as Yorvipath was cleared by the U.S. FDA in August 2024 for hypoparathyroidism.
Advertisement